Guanine nucleotide exchange factor-H1 signaling is critical for induction of anti-tumor immunity induced by microtubule-depolymerizing drugs

Kashyap AS^{1,2}, Zhao Y², Martin K¹, Omatsu T², Lloyd KG³, Huang L³, Reinecker HC², Zippelius A¹

¹Dept. of Biomedicine, University Hospital Basel, Switzerland; ²Gastrointestinal Unit, Massachusetts General Hospital, USA; ³BeyondSpring Pharmaceuticals, New York, USA

Introduction

The immuno-suppressive tumor microenvironment poses a major hurdle for anti-tumor immunity and for the targeting of immune checkpoint inhibitory receptors such as CTLA-4 and PD1.

□ We have shown that contrary to microtubule stabilizing agents (MSA) tubulin de-polymerizing agents (MDA) such as plinabulin (currently in Phase 3 in NSCLC), auristatins and maytansinoids reprogram the tumor immune environment by activating DCs and priming of anti-tumour T cells^{1,2}.

MDAs were shown in pre-clinical models to boost the activity of anti-PD1 and anti-CTLA4³.



Fig 1: Model of MDA-induced anti-tumor immunity

□ The mechanism behind MDA-induced dendritic cell (DC) activation remains unaddressed and is the focus of this study.

Hypothesis

DC activation induced by MDAs is independent of pattern-recognition receptors (PRR), but is rather dependent on the direct disruption of microtubules and the subsequent activation of downstream signaling cascades.



- 1. Mueller P, et al. 2014. Cancer Immunol Res.
- 2. Martin K, et al. 2014. *Cancer Immunol Immunother*.
- 3. Mueler P, et al. 2015. *Sci Trans Med.*

Results

MDAs and not MSAs stimulate DC activation: this is independent of microtubule binding site



Fig 2: SP37A3 DC cells were treated with 1 μM of different MDAs and MSAs targeting distinct microtubule binding sites. CD86 and CD80 expression was assessed by FACS.

MDA-induced DC activation is independent of PRRs



Fig 3: BMDCs from WT/KO mice were treated with MDAs (100 nM) or controls for 24h. CD80 and CD86 expression was assessed by FACS and IL1 β measured by ELISA. MDAinduced DC activation remained unaffected in the KO mice

Microtubule associated Guanine nucleotide exchange factor (GEFH1) is released from microtubules upon treatment with Ansamitocin-P3



Fig 5: GEFH1 was immunoprecipitated from WT and GEFH1^{-/-} BMDCs treated with Ansamitocin-P3 or Paclitaxel (100 nM) for indicated time-points. No GEFH1 was detected in GEFH1^{-/-} BMDCs. Active GEFH1 (dephosphorylated) was detected with Ansamitocin-P3 at 30 mins (blots and densitometry graphs). GEFH1 remained inactive (phosphorylated) with Paclitaxel.

GEFH1 release and activation triggers conversion RhoA-GDP to RhoA-GTP





Fig 6: Total protein from SP37A3 DCs treated with Ansamitocin-P3 was added to G-LISA plates and Rho-GTP was measured. Rho-GTP was observed within 30 mins after treatment.

MDAs recruit the MKK4/JNK/cJun signaling axis to induce DC activation in a GEFH1-dependent manner





Fig 7: Lysates from WT or GEFH1^{-/-} BMDCs treated with AnsaP3 or Paclitaxel were probed for phospho or total protein. Although ERK and NFkB activation was GEFH1 dependent (A) it was observed in both AnsaP3 and Paclitaxel. However, MKK4, JNK and cJun remained uniquely activated in AnsaP3 (B) and was GEFH1 dependent.



Fig 8: In GEFH1^{-/-} BMDCs (A) and XS106 DC cells (B) the MDAs AnsaP3 and Plinabulin were unable to induce DC activation. Reduced activation of GEFH1^{-/-} BMDCs lead to suboptimal expansion of OVA-specific CD8 T cells (C). No effect on CD4 T cells was observed (D). Together, this suggests that GEFH1 is critical for MDA-induced DC activation and function.



Acknowledgements: The work is supported by BeyondSpring Pharmaceuticals, Wilhelm Sander Stiftung, Swiss National Fund International Travel grant, Huggenberger-Bischoffs Stiftung and Bio-Techne travel grant. Contact: abhishek.kashyap@unibas.ch

GEFH1 is critically involved in MDA-induced DC activation and function

Model - MoA